The chemical company, Enantia, finalises its sale to the venture capital management company, Inveready
Enantia, a contract research organisation (CRO) that specialises in preclinical studies for small molecule drugs, has closed its sale to the venture capital management company, Inveready, which aims to promote a range of R&D services in the pharmaceutical field
Enantia offers comprehensive services related to chemicals for companies in the pharmaceutical and biotechnology sectors, covering everything from initial research to the development of chemical processes, including all other stages of research. The investment by Inveready will contribute to the promotion of new projects and the development of future products, as well as expanding the international presence of Enantia.
A team led by Oscar Alegre, Miquel Campos, and Oriol Noguer advised Enantia on this transaction.
